Cargando…
Gestione clinica della terapia con Denosumab: in chi, quando e come interromperla
Denosumab (Dmab) is a potent antiresorptive agent approved for treatment of osteoporosis at a dose of 60 mg subcutaneously every 6 months. Differently from bisphosphonates, Dmab is not incorporated in the bone matrix and interruption or delay in its administration leads to a well-known rebound effec...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906587/ http://dx.doi.org/10.1007/s40619-023-01207-8 |